Definition of stereotactic body radiotherapy

This report from the Stereotactic Radiotherapy Working Group of the German Society of Radiation Oncology (Deutschen Gesellschaft für Radioonkologie, DEGRO) provides a definition of stereotactic body radiotherapy (SBRT) that agrees with that of other international societies. SBRT is defined as a method of external beam radiotherapy (EBRT) that accurately delivers a high irradiation dose to an extracranial target in one or few treatment fractions. Detailed recommendations concerning the principles and practice of SBRT for early stage non-small cell lung cancer (NSCLC) are given. These cover the entire treatment process; from patient selection, staging, treatment planning and delivery to follow-up. SBRT was identified as the method of choice when compared to best supportive care (BSC), conventionally fractionated radiotherapy and radiofrequency ablation. Based on current evidence, SBRT appears to be on a par with sublobar resection and is an effective treatment option in operable patients who refuse lobectomy.ZusammenfassungDie Arbeitsgruppe „Stereotaktische Radiotherapie“ der Deutschen Gesellschaft für Radioonkologie (DEGRO) erarbeitete eine Definition der Körperstereotaxie (SBRT), die sich an vorhandene internationale Definitionen anlehnt: Die SBRT ist eine Form der perkutanen Strahlentherapie, die mit hoher Präzision eine hohe Bestrahlungsdosis in einer oder wenigen Bestrahlungsfraktionen in einem extrakraniellen Zielvolumen appliziert. Zur Praxis der SBRT beim nichtkleinzelligen Bronchialkarzinom (NSCLC) im frühen Stadium werden detaillierte Empfehlungen gegeben, die den gesamten Ablauf der Behandlung von der Indikationsstellung, Staging, Behandlungsplanung und Applikation sowie Nachsorge umfassen. Die Körperstereotaxie wurde als Methode der Wahl im Vergleich zu Best Supportive Care, zur konventionell fraktionierten Strahlentherapie sowie zur Radiofrequenzablation identifiziert. Die Ergebnisse nach SBRT und sublobärer Resektion erscheinen auf aktueller Datenbasis ebenbürtig. Die SBRT ist die Methode der Wahl, wenn Patienten einen operativen Eingriff in Form der Lappenresektion ablehnen.

[1]  A. Bezjak,et al.  The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  Z. Fuks,et al.  Engaging the vascular component of the tumor response. , 2005, Cancer cell.

[3]  S. Raoof,et al.  A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. , 2013, Chest.

[4]  Y. Shibamoto,et al.  Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. , 2012, International journal of radiation oncology, biology, physics.

[5]  C. Williams,et al.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review , 2001, The Cochrane database of systematic reviews.

[6]  T. Kimura,et al.  CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? , 2006, International journal of radiation oncology, biology, physics.

[7]  H. Groen,et al.  Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Tsumatori,et al.  Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients , 1998, Cancer.

[9]  S. Senan,et al.  Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  F Lohr,et al.  Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. , 2000, International journal of radiation oncology, biology, physics.

[11]  M. Licker,et al.  Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. , 1999, The European respiratory journal.

[12]  S. Ou,et al.  Natural history of stage I non-small cell lung cancer: implications for early detection. , 2007, Chest.

[13]  Y. Onodera,et al.  Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[14]  Mike Partridge,et al.  Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  S. Cummings,et al.  Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach. , 1986, The American review of respiratory disease.

[16]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[17]  Ke Sheng,et al.  Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.

[18]  Nasser K. Altorki,et al.  Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. , 2009, The Journal of thoracic and cardiovascular surgery.

[19]  S. Kuribayashi,et al.  Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. , 2004, AJR. American journal of roentgenology.

[20]  David J Brenner,et al.  The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. , 2008, Seminars in radiation oncology.

[21]  C. Reddy,et al.  Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). , 2009, International journal of radiation oncology, biology, physics.

[22]  R. Rengan,et al.  Stereotactic body radiotherapy. , 2014, Seminars in oncology.

[23]  Thierry Gevaert,et al.  Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. , 2011, International journal of radiation oncology, biology, physics.

[24]  Alfons G H Kessels,et al.  Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Kurt Baier,et al.  Dose-response in stereotactic irradiation of lung tumors. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[27]  Joe Y. Chang,et al.  Clinical Investigation : Thoracic Cancer Comparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly , 2012 .

[28]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Hong Ye,et al.  Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Suresh Senan,et al.  Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.

[31]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[32]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[33]  S. Swensen,et al.  The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. , 1997, Archives of internal medicine.

[34]  Thomas Krieger,et al.  Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. , 2005, International journal of radiation oncology, biology, physics.

[35]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy: what's in a name? , 2011, Practical radiation oncology.

[36]  U Oppitz,et al.  Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[38]  Y. Shim,et al.  Occult nodal metastasis in patients with non‐small cell lung cancer at clinical stage IA by PET/CT , 2010, Respirology.

[39]  I. Paddick,et al.  A simple scoring ratio to index the conformity of radiosurgical treatment plans , 2001 .

[40]  M. Anscher,et al.  Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. , 1998, International journal of radiation oncology, biology, physics.

[41]  F. Sterzing,et al.  Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  E. Smit,et al.  Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis. , 2012 .

[43]  P Kirkbride,et al.  Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[44]  J. Sonke,et al.  Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  I. Lax,et al.  Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. , 1994, Acta oncologica.

[46]  J. Itami,et al.  Stereotactic Body Radiotherapy for Lung Tumors at the Pulmonary Hilum , 2009, Strahlentherapie und Onkologie.

[47]  Joachim Widder,et al.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study , 2009, Radiation oncology.

[48]  Umberto Ricardi,et al.  Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. , 2010, Lung cancer.

[49]  Suresh Senan,et al.  European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Petersen,et al.  Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  Jose Belderbos,et al.  Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  I. Paddick.  A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. , 2000, Journal of neurosurgery.

[53]  S. Senan,et al.  Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  R K Ten Haken,et al.  Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. , 1999, Lung cancer.

[55]  C. Bolliger,et al.  Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. , 1995, Chest.

[56]  R. Rosenfeld.  Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[57]  Ke Sheng,et al.  Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[58]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[59]  Jan-Jakob Sonke,et al.  Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. , 2008, International journal of radiation oncology, biology, physics.

[60]  S. Raoof,et al.  A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. , 2013, Chest.

[61]  Lawrence B Marks,et al.  The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. , 2008, Seminars in radiation oncology.

[62]  Kurt Baier,et al.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[63]  Suresh Senan,et al.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[64]  Laura N. Medford-Davis,et al.  Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. , 2012 .

[65]  Matthias Guckenberger,et al.  Cone-beam CT based image-guidance for extracranial stereotactic radiotherapy of intrapulmonary tumors , 2006, Acta oncologica.

[66]  I. Oze,et al.  Evaluation of resected tumors that were not diagnosed histologically but were suspected of lung cancer preoperatively: PD1-3-5 , 2007 .

[67]  R. Timmerman,et al.  Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). , 2013, The Journal of thoracic and cardiovascular surgery.

[68]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[69]  Lech Papiez,et al.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.

[70]  Matthias Guckenberger,et al.  Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[71]  Samuel Ryu,et al.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. , 2004, International journal of radiation oncology, biology, physics.

[72]  Suresh Senan,et al.  Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. , 2012, International journal of radiation oncology, biology, physics.

[73]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[74]  J. Sonke,et al.  A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  Michael Flentje,et al.  Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[76]  S. Senan,et al.  Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[77]  Wei Huang,et al.  Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. , 2011, International journal of radiation oncology, biology, physics.

[78]  Matthias Guckenberger,et al.  Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[79]  Jan Nyman,et al.  Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  P. Falcoz,et al.  Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? , 2013, Interactive cardiovascular and thoracic surgery.

[81]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[82]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.